Cochrane · systematic review · CD009455
Naproxen with or without an antiemetic for acute migraine headaches in adults
Law, S, Derry, S, Moore, RA · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 4 · 66.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Naproxen 500 mg or 825 mg compared with placebo for migraine headache
Population: migraine headache ‐ moderate or severe pain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain‐free response at 2 h Naproxen 500 mg or 825 mg vs placebo | no estimate extracted | NR | Moderate Downgraded: inconsistency, publication bias |
Headache relief at 2 h Naproxen 500 mg or 825 mg vs placebo | no estimate extracted | NR | Moderate Downgraded: inconsistency, publication bias |
Sustained pain‐free during the 24 h post dose Naproxen 500 mg or 825 mg vs placebo | no estimate extracted | NR | Moderate Downgraded: inconsistency, publication bias |
Sustained headache relief during the 24 h post dose Naproxen 500 mg or 825 mg vs placebo | no estimate extracted | NR | Moderate Downgraded: inconsistency, publication bias |
At least one AE Naproxen 500 mg or 825 mg vs placebo | no estimate extracted | NR | Low Downgraded: inconsistency, publication bias |
Serious AE Naproxen 500 mg or 825 mg vs placebo | no estimate extracted | NR | No studies |